How Dendreon's (NASDAQ: DNDN) drug Provenge performs in sequence with Johnson & Johnson's drug Zytiga to treat advanced stage prostate cancer is crucial to the company's near- to mid-term success. In this video, Motley Fool health care analyst David Williamson discusses the possible outcomes and how Dendreon will move forward if the clinical trial is a failure.